Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma.
Epstein-Barr virus
adult glioma
antibodies to varicella-zoster virus
cytomegalovirus
glioblastoma
herpes simplex virus
survival
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 06 2023
02 06 2023
Historique:
pmc-release:
04
01
2024
medline:
5
6
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
Lifetime exposure to the varicella-zoster virus (VZV) has been consistently inversely associated with glioma risk, however, the relationship of VZV with survival in adults with glioma has not been investigated. In this study, we analyzed the survival of adults with glioma in relation to their antibody measurements to 4 common herpes viral infections, including VZV, measured post-diagnosis. We analyzed IgG antibody measurements to VZV, cytomegalovirus (CMV), herpes simplex virus 1/2 (HSV), and Epstein-Barr virus (EBV) collected from 1378 adults with glioma diagnosed between 1991 and 2010. Blood was obtained a median of 3 months after surgery. Associations of patient IgG levels with overall survival were estimated using Cox models adjusted for age, sex, self-reported race, surgery type, dexamethasone usage at blood draw, and tumor grade. Models were stratified by recruitment series and meta-analyzed to account for time-dependent treatment effects. VZV antibody seropositivity was associated with improved survival outcomes in adults with glioma (Hazard ratio, HR = 0.70, 95% Confidence Interval 0.54-0.90, P = .006). Amongst cases who were seropositive for VZV antibodies, survival was significantly improved for those above the 25th percentile of continuous reactivity measurements versus those below (HR = 0.76, 0.66-0.88, P = .0003). Antibody seropositivity to EBV was separately associated with improved survival (HR = 0.71, 0.53-0.96, P = .028). Antibody positivity to 2 other common viruses (CMV, HSV) was not associated with altered survival. Low levels of VZV or EBV antibodies are associated with poorer survival outcomes for adults with glioma. Differential immune response rather than viral exposure may explain these findings.
Sections du résumé
BACKGROUND
Lifetime exposure to the varicella-zoster virus (VZV) has been consistently inversely associated with glioma risk, however, the relationship of VZV with survival in adults with glioma has not been investigated. In this study, we analyzed the survival of adults with glioma in relation to their antibody measurements to 4 common herpes viral infections, including VZV, measured post-diagnosis.
METHODS
We analyzed IgG antibody measurements to VZV, cytomegalovirus (CMV), herpes simplex virus 1/2 (HSV), and Epstein-Barr virus (EBV) collected from 1378 adults with glioma diagnosed between 1991 and 2010. Blood was obtained a median of 3 months after surgery. Associations of patient IgG levels with overall survival were estimated using Cox models adjusted for age, sex, self-reported race, surgery type, dexamethasone usage at blood draw, and tumor grade. Models were stratified by recruitment series and meta-analyzed to account for time-dependent treatment effects.
RESULTS
VZV antibody seropositivity was associated with improved survival outcomes in adults with glioma (Hazard ratio, HR = 0.70, 95% Confidence Interval 0.54-0.90, P = .006). Amongst cases who were seropositive for VZV antibodies, survival was significantly improved for those above the 25th percentile of continuous reactivity measurements versus those below (HR = 0.76, 0.66-0.88, P = .0003). Antibody seropositivity to EBV was separately associated with improved survival (HR = 0.71, 0.53-0.96, P = .028). Antibody positivity to 2 other common viruses (CMV, HSV) was not associated with altered survival.
CONCLUSIONS
Low levels of VZV or EBV antibodies are associated with poorer survival outcomes for adults with glioma. Differential immune response rather than viral exposure may explain these findings.
Identifiants
pubmed: 36610073
pii: 6968603
doi: 10.1093/neuonc/noac283
pmc: PMC10237424
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1047-1057Subventions
Organisme : NCI NIH HHS
ID : R01 CA139020
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA151022
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA112355
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA126831
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097257
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207360
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA266676
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Infect Dis. 2013 Oct 15;208(8):1286-93
pubmed: 23868878
Am J Hum Genet. 2022 Jun 2;109(6):1105-1116
pubmed: 35550063
Cancer Res. 2006 Apr 15;66(8):4531-41
pubmed: 16618782
Lancet. 1964 Mar 28;1(7335):702-3
pubmed: 14107961
Clin Cancer Res. 2013 Jun 15;19(12):3165-75
pubmed: 23613317
Nat Rev Neurol. 2019 Jul;15(7):405-417
pubmed: 31227792
Cancer Med. 2016 Jun;5(6):1352-8
pubmed: 26972449
Neuro Oncol. 2020 Nov 26;22(11):1602-1613
pubmed: 32386320
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945
Nat Genet. 2009 Aug;41(8):905-8
pubmed: 19578366
Acta Neuropathol Commun. 2016 Jul 11;4(1):71
pubmed: 27402152
Virology. 1962 Dec;18:582-8
pubmed: 13947330
BMC Infect Dis. 2018 May 25;18(1):238
pubmed: 29801466
J Neuroimmunol. 1999 Jan 1;93(1-2):1-7
pubmed: 10378863
MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40
pubmed: 17585291
Neuro Oncol. 2010 Nov;12(11):1113-25
pubmed: 20667896
Infect Agent Cancer. 2016 Jul 26;11:32
pubmed: 27462365
J Med Virol. 2003;70 Suppl 1:S111-8
pubmed: 12627498
Clin Infect Dis. 2006 Nov 1;43(9):1143-51
pubmed: 17029132
BMC Cancer. 2020 Jun 12;20(1):549
pubmed: 32532243
Oncoimmunology. 2018 Oct 16;8(1):e1514921
pubmed: 30546954
J Neurooncol. 2011 Dec;105(3):451-66
pubmed: 21720806
Int J Cancer. 2022 Jul 15;151(2):222-228
pubmed: 35225352
Curr Res Transl Med. 2019 Nov;67(4):129-133
pubmed: 31501045
Acta Neuropathol. 2008 Jul;116(1):79-86
pubmed: 18351367
Science. 1973 Aug 17;181(4100):674-6
pubmed: 4353360
Neuro Oncol. 2012 Mar;14(3):246-55
pubmed: 22319219
J Immunother Cancer. 2018 Jun 11;6(1):51
pubmed: 29891009
Sci Signal. 2010 Aug 03;3(133):ra58
pubmed: 20682912
Am J Epidemiol. 2005 May 15;161(10):929-38
pubmed: 15870157
Gene Ther Mol Biol. 2006;10(A):133-146
pubmed: 16810329
Int J Cancer. 2014 May 1;134(9):2199-210
pubmed: 24127236
J Clin Neurosci. 2015 Feb;22(2):326-30
pubmed: 25443081
JAMA. 2006 Aug 23;296(8):964-73
pubmed: 16926356
Front Oncol. 2018 Apr 20;8:123
pubmed: 29732319
MMWR Morb Mortal Wkly Rep. 2016 Sep 02;65(34):902-5
pubmed: 27584717
Public Health Rep. 2010 Nov-Dec;125(6):860-9
pubmed: 21121231
Front Mol Biosci. 2022 Jan 10;8:816098
pubmed: 35083281
J Cereb Blood Flow Metab. 2013 Jan;33(1):13-21
pubmed: 23072749
PLoS One. 2014 May 14;9(5):e97407
pubmed: 24827739
J Neurovirol. 2011 Oct;17(5):448-54
pubmed: 21792750
Cancer Res. 2002 Jun 15;62(12):3347-50
pubmed: 12067971
J Neurovirol. 2021 Feb;27(1):94-100
pubmed: 33405205
Am J Epidemiol. 1997 Apr 1;145(7):594-7
pubmed: 9098175
Intern Med. 2003 Jan;42(1):33-40
pubmed: 12583615
Neuro Oncol. 2005 Jul;7(3):213-24
pubmed: 16053696